Challenges of the eighth edition of the American Joint Committee on Cancer staging system for pathologists focusing on early stage lung adenocarcinoma
Thoracic Cancer · 2023-02 · 14 (6) · 592-601
DOI: 10.1111/1759-7714.14785 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 02.01.2023. Verfasst von Yu-Ting Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical Pathology, Chung Shan Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health and Welfare, National Health Research Institutes.
Abstract (Originalsprache)
Background
The eighth edition of the American Joint Committee on Cancer (AJCC) staging system for lung cancer adopts new criteria for tumor size, and for determining pTis, pT1a(mi), and pT1a. The latter is based on the size of stromal invasion. It is quite challenging for lung pathologists.
Methods
All patients who had undergone surgical resection for pulmonary adenocarcinoma (ADC) at Chung Shan Medical University Hospital between January 2014 and April 2018 were reviewed, and restaged according to the eighth AJCC staging system. The clinical characteristics and survival of patients with tumor stage 0 (pTis), I or II were analyzed.
Results
In total, 376 patients were analyzed. None of the pTis, pT1a(mi), or pT1a tumors recurred during the follow‐up period up to 5 years, but pT1b, pT1c, pT2a, and pT2b tumors all had a few tumor recurrences ( p < 0.0001). In addition, 95.2%, 100%, and 77.5% of pTis, pT1a(mi), and pT1a tumors, respectively, had tumor sizes ≤1.0 cm by gross examination. All pTis, pT1a(mi), and pT1a tumors exhibited only lepidic, acinar, or papillary patterns histologically.
Conclusions
This study demonstrated excellent survival for lung ADC patients with pTis, pT1a(mi), and pT1a tumors when completely excised. To reduce the inconsistencies between pathologists, staging lung ADC with tumors of ≤1 cm in size grossly as pTis, pT1a(mi), or pT1a may not be necessary when the tumors exhibit only lepidic, acinar, or papillary histological patterns. A larger cohort study with sufficient follow‐up data is necessary to support this proposal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anatomical Pathology, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.
- Department of Thoracic Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
ORCID-Profile: Shiu-Feng Huang
Förderung
- Ministry of Health and Welfare
- National Health Research Institutes
Zitieren
APA
Wang, Y. T., Chang, I. C., Chen, C. Y., Hsia, J. Y., Lin, F. C., Chao, W. R., Ke, T. Y., Chen, Y. T., Chen, C. J., Hsieh, M. S., & Huang, S. F. (2023). Challenges of the eighth edition of the American Joint Committee on Cancer staging system for pathologists focusing on early stage lung adenocarcinoma. Thoracic Cancer, 14(6), 592-601. https://doi.org/10.1111/1759-7714.14785
Vancouver
Wang YT, Chang IC, Chen CY, Hsia JY, Lin FC, Chao WR, et al. Challenges of the eighth edition of the American Joint Committee on Cancer staging system for pathologists focusing on early stage lung adenocarcinoma. Thoracic Cancer. 2023;14(6):592-601. doi:10.1111/1759-7714.14785
BibTeX
@article{Wang2023,
author = {Wang, Yu-Ting and Chang, Il-Chi and Chen, Chih-Yi and Hsia, Jiun-Yi and Lin, Frank Cheau-Feng and Chao, Wan-Ru and Ke, Tuan-Ying and Chen, Ya-Ting and Chen, Chih-Jung and Hsieh, Min-Shu and Huang, Shiu-Feng},
title = {Challenges of the eighth edition of the American Joint Committee on Cancer staging system for pathologists focusing on early stage lung adenocarcinoma},
journal = {Thoracic Cancer},
year = {2023},
volume = {14},
number = {6},
pages = {592--601},
doi = {10.1111/1759-7714.14785}
}
EUVIMED